Table 3. Relevant canonical pathways identified by IPA, in which those with −log(P value) >1.3 were selected, corresponding to P value <0.05.
| No. | Ingenuity canonical pathways | −log(P value) | Ratio | Molecules |
|---|---|---|---|---|
| 1 | LXR/RXR activation | 4.89 | 0.07 | APOE, PON1, HPX, ITIH4, ACACA, S100A8, A1BG, RBP4 |
| 2 | Acute phase response signaling | 4.54 | 0.05 | PLG, HPX, FTL, HP, FN1, ITIH4, CP, C2, RBP4 |
| 3 | Atherosclerosis signaling | 4.00 | 0.06 | APOE, PON1, MMP3, CMA1, COL2A1, S100A8, RBP4 |
| 4 | Granzyme A signaling | 3.12 | 0.16 | Hist1h1d, APEX1, HIST1H1B |
| 5 | TR/RXR activation | 2.93 | 0.06 | HP, COL6A3, ACACA, G6PC, ME1 |
| 6 | Clathrin-mediated endocytosis signaling | 2.79 | 0.04 | APOE, PON1, RAB5A, CLTA, S100A8, AP2S1, RBP4 |
| 7 | Role of IL-17A in psoriasis | 2.50 | 0.22 | S100A9, S100A8 |
| 8 | Remodeling of epithelial adherens junctions | 2.45 | 0.06 | TUBA1A, RAB5A, TUBA4A, Actn3 |
| 9 | Actin cytoskeleton signaling | 2.37 | 0.03 | MYH4, TLN2, FN1, MYLPF, Actn3, GSN, MYL1 |
| 10 | Calcium signaling | 2.21 | 0.03 | MYH4, TNNC2, TNNT3, Tpm1, MYL1, PRKAR1A |
| 11 | EIF2 signaling | 2.08 | 0.03 | RPL6, RPL4, RPL5, RPS9, Eif4a3, RPL18 |
| 12 | Acetyl-CoA biosynthesis III (from Citrate) | 2.02 | 1.00 | ACLY |
| 13 | Asparagine biosynthesis I | 2.02 | 1.00 | ASNS |
| 14 | Glutathione redox reactions I | 1.94 | 0.12 | GPX3, GPX1 |
| 15 | Epithelial adherens junction signaling | 1.91 | 0.04 | MYH4, TUBA1A, TUBA4A, Actn3, MYL1 |
| 16 | Germ cell-sertoli cell junction signaling | 1.80 | 0.03 | TUBA1A, PPAP2B, TUBA4A, Actn3, GSN |
| 17 | Dopamine degradation | 1.76 | 0.10 | ALDH2, Sult1a1 |
| 18 | Glycolysis I | 1.65 | 0.08 | PKM, ENO2 |
| 19 | Gluconeogenesis I | 1.65 | 0.08 | ENO2, ME1 |
| 20 | Sertoli cell-sertoli cell junction signaling | 1.59 | 0.03 | TUBA1A, PPAP2B, TUBA4A, Actn3, PRKAR1A |
| 21 | IL-12 signaling and production in macrophages | 1.56 | 0.03 | APOE, PON1, S100A8, RBP4 |
| 22 | Protein kinase A signaling | 1.56 | 0.02 | MYH4, PYGM, MYLPF, Hist1h1d, APEX1, HIST1H1B MYL1, PRKAR1A |
| 23 | ILK signaling | 1.52 | 0.03 | MYH4, FN1, PPAP2B, Actn3, MYL1 |
| 24 | Caveolar-mediated endocytosis signaling | 1.49 | 0.04 | RAB5A, CAV1, CD48 |
| 25 | Cellular effects of sildenafil (viagra) | 1.48 | 0.03 | MYH4, MYLPF, MYL1, PRKAR1A |
| 26 | Complement system | 1.45 | 0.06 | CFD, C2 |
| 27 | AMPK signaling | 1.43 | 0.03 | Ak1, CKM, ACACA, PRKAR1A |
| 28 | Creatine-phosphate biosynthesis | 1.42 | 0.25 | CKM |
| 29 | Phenylethylamine degradation I | 1.42 | 0.25 | ALDH2 |
| 30 | Biotin-carboxyl carrier protein assembly | 1.42 | 0.25 | ACACA |
| 31 | Regulation of actin-based motility by Rho | 1.39 | 0.04 | MYLPF, GSN, MYL1 |
| 32 | Neuroprotective role of THOP1 in Alzheimer’s disease | 1.33 | 0.05 | PLG, PRKAR1A |
| 33 | FXR/RXR activation | 1.32 | 0.04 | APOE, PON1, G6PC |
| 34 | CTLA4 signaling in cytotoxic T lymphocytes | 1.30 | 0.03 | CLTA, HLA-DRA, AP2S1 |
IPA, ingenuity pathway analysis.